Treating ICI-related diarrhea or colitis with ustekinumab
Treatments studied
Part of Cancer clinical trials.
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older
- You must have had diarrhea or colitis from immunotherapy that is moderate or severe
- You must have a solid tumor cancer and be on or have recently taken immunotherapy
- You cannot have an active gut infection that hasn't been treated
- You cannot have active inflammatory bowel disease or radiation-related colitis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
This trial studies whether infliximab can treat stomach inflammation in the colon (colitis) or frequent diarrhea caused by immune checkpoint cancer drugs. It aims to improve symptoms safely for adults with certain solid cancers.
This trial tests whether a combination of two drugs (upadacitinib and ustekinumab) works better than a higher dose of ustekinumab alone for people with active Crohn's disease that hasn't responded well to previous treatments.
This trial tests an investigational oral medication (SER-155) for people whose diarrhea is caused by immunotherapy. It aims to calm the gut and reduce symptoms without needing stronger drugs.
This study tests whether vedolizumab, a drug that reduces gut inflammation, can prevent diarrhea caused by immunotherapy (a type of cancer treatment). It is for adults with advanced melanoma, lung, or kidney cancer who have a stool marker of inflammation early in treatment.
This study follows adults with Crohn’s disease or ulcerative colitis to compare the long-term safety of ustekinumab against other biologic medicines. It may help show how safe these treatments are over time, using medical records.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.